Related Experiment Video
Updated: Nov 16, 2025

10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.7K
Changes in Body Composition Before and After Parkinson's Disease Diagnosis
Shengfang Song1, Zhehui Luo1, Chenxi Li1
1Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.
Movement Disorders : Official Journal of the Movement Disorder Society
|February 22, 2021
Summary
Parkinson's disease (PD) is linked to significant weight loss, primarily of fat mass, beginning years before diagnosis. Lean mass remained stable, indicating fat loss is the main driver of weight changes in PD.
Area of Science:
- Neurology
- Gerontology
- Metabolic Research
Background:
- Weight loss is a common but poorly understood symptom in Parkinson's disease (PD).
- Limited knowledge exists regarding the timing and progression of body composition changes in PD.
- The differential loss of lean versus fat mass in PD progression remains unclear.
Purpose of the Study:
- To investigate the changes in body composition over time in individuals with Parkinson's disease.
- To determine when body mass and composition alterations begin relative to PD diagnosis.
- To differentiate between lean and fat mass loss in the context of Parkinson's disease progression.
Main Methods:
- Utilized data from the Health, Aging, and Body Composition study (n=3075).
- Assessed body composition annually/biennially using dual-energy x-ray absorptiometry over 10 years.
- Employed linear mixed models to analyze trends in body composition changes before and after PD diagnosis.
Main Results:
- Identified 80 PD cases within the cohort.
- PD cases showed significant loss of total and fat mass starting 6-7 years pre-diagnosis.
- Statistically significant trends of loss were observed for total body mass, fat mass, and percentage fat post-diagnosis; lean mass remained stable.
- 96% of body mass loss in PD cases was attributed to fat mass reduction.
Conclusions:
- This longitudinal study demonstrates persistent weight loss in Parkinson's disease, predominantly fat mass.
- Significant fat mass loss begins several years prior to clinical PD diagnosis.
- Body composition analysis reveals that fat mass depletion, not lean mass, characterizes weight changes in PD.
Related Concept Videos
Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
Parkinson's Disease: Treatment
743
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
743
Neural Regulation
41.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
41.6K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
100
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
100

